Björck S, Svalander C, Westberg G
Acta Med Scand. 1985;218(3):261-9. doi: 10.1111/j.0954-6820.1985.tb06123.x.
Nine patients (6 men, 3 women) with rapidly progressive glomerulonephritis developing during hydralazine therapy were seen. Early cessation of hydralazine treatment resulted in improvement in seven patients, while continued hydralazine treatment resulted in permanent renal insufficiency in two. The clinical symptoms of systemic illness associated with the hydralazine syndrome were absent in most patients. Antinuclear antibody test was positive in all, and six investigated patients had antibodies to histones. All patients had anemia, high ESR, and microscopic hematuria. Five of the nine patients were rapid drug acetylators. Renal biopsies from eight patients revealed a uniform histologic picture with segmental necrosis of glomeruli and extracapillary proliferation. Immunofluorescence investigation was positive in all and electron microscopy revealed deposits in the glomerular capillary walls in five of seven specimens. This renal disease may represent a late and monosymptomatic manifestation of the hydralazine syndrome.
我们观察到9例在肼屈嗪治疗期间发生快速进展性肾小球肾炎的患者(6例男性,3例女性)。早期停用肼屈嗪治疗使7例患者病情改善,而继续使用肼屈嗪治疗导致2例患者出现永久性肾功能不全。大多数患者没有与肼屈嗪综合征相关的全身性疾病临床症状。所有患者抗核抗体检测均为阳性,6例接受调查的患者有组蛋白抗体。所有患者均有贫血、血沉增快和镜下血尿。9例患者中有5例是快速药物乙酰化者。8例患者的肾活检显示出一致的组织学表现,即肾小球节段性坏死和球囊外增生。所有患者免疫荧光检查均为阳性,7个标本中有5个经电子显微镜检查显示肾小球毛细血管壁有沉积物。这种肾脏疾病可能是肼屈嗪综合征的一种晚期单症状表现。